Shares of Dr Reddys Laboratories today rose by nearly 3 per cent after the company said the USFDA has completed its API Srikakulam plant audit with no observations.
The stock went up by 2.86 per cent to close at Rs 1,996.95 on the BSE. During the day, it jumped 4.25 per cent to Rs 2,024.05. On the NSE, shares of the company gained by 2.4 per cent to end at Rs 1,988.
The stock was the biggest gainer among the blue chips on both the key indices.
The company's market valuation rose by Rs 912.62 crore to Rs 33,122.62 crore.
On the equity volume front, 1 lakh shares of the company were traded on BSE and over 14 lakh shares changed hands on the NSE during the day.
In a filing to the BSE on Saturday, Dr Reddy's said, "This is to inform you that the audit of our API Srikakulam plant (SEZ), Andhra Pradesh by the USFDA, has been completed with no observations.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app